This study discusses how the therapy of severe asthma has progressed from a “blockbuster” strategy to a more customized one focused on the use of endotype-driven medicines. The characterization of severe asthma in phenotypes and endotypes using particular biomarkers has resulted in the dichotomization of the notions of ‘personalized medicine’ and ‘precision medicine,’ which are frequently used as synonyms but have fundamental distinctions in meaning. The recent contribution of omic sciences (e.gproteomics, transcriptomics, metabolomics, genomes, etc.) has taken this initially theoretical progression to a more tangible level.
This gradual transition would result in a better approach to severe asthmatic patients, as personalization of their therapeutic strategy would result in better patient selection, more precise endotype-driven treatment, and hopefully better outcomes in terms of exacerbation rates, symptoms, pulmonary function, and quality of life.
